Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Iowa Sohonos Policy Update | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - IowaPolicy 05.05.17

    Sohonos (palovarotene) coverage for fibrodysplasia ossificans progressiva

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Iowa Policy 05.05.17 alerts

    Get alerted when Policy 05.05.17 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and coverage of Sohonos (palovarotene) for reducing new heterotopic ossification in members with fibrodysplasia ossificans progressiva (FOP). Coverage applies when the specified diagnosis, age, safety, reproductive-status, specialist, and response-to-therapy requirements are met.

    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicySohonos (palovarotene) coverage for fibrodysplasia ossificans progressiva
    Policy CodePolicy 05.05.17
    Change TypeNo material clinical or coverage change
    Effective DateDec 9, 202621d
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization to initiate or continue Sohonos treatment.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsInitial and continuation authorization period
    Male age 10+Minimum age for male members
    Female age 8+Minimum age for female members
    ACVR1 variantGenetic confirmation required for initial approval

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Pasatru excludedConcurrent use with garetosmab-grts is not permitted

    Coverage Criteria

    Initial Therapy Criteria

    Authorization of 12 months may be granted when all of the following criteria are met.

    Initial approval

    • Diagnosis and clinical findings: Member has a pathogenic ACVR1 FOP-causing variant, such as R206H, and signs and symptoms of FOP, such as congenital malformation of the great toe and episodic soft-tissue swelling and/or ectopic ossification in ligament or muscle tissue.
    • Medical stability: Member has no significant uncontrolled comorbid illness, such as cardiac, neurologic, or rheumatologic illness.
    • Age requirement

      • Male age criterion: Member is male and 10 years of age or older.>=10 years
      • Female age criterion: Member is female and 8 years of age or older.>=8 years
    • Reproductive safety: Females of reproductive potential have a negative pregnancy test; the member is not currently breastfeeding, pregnant, or planning pregnancy.Negative pregnancy test when applicable
    • Combination restriction: Sohonos will not be used in combination with Pasatru (garetosmab-grts).

    Continuation Therapy Criteria

    Authorization of 12 months may be granted for continued treatment when the continuation criteria are met.

    Continuation therapy

    • Age requirement

      • Male age criterion: Member is male and 10 years of age or older.>=10 years
      • Female age criterion: Member is female and 8 years of age or older.>=8 years
    • Therapeutic benefit: Member is experiencing benefit from therapy, evidenced by disease stability or improvement, such as stability or reduction in the volume of new heterotopic ossification.

    Sohonos (palovarotene) is not covered when used in combination with Pasatru (garetosmab-grts). Concurrent use of these medications is excluded from coverage for both initial and continuation therapy.

    Coverage is excluded when the member is pregnant, breastfeeding, or planning pregnancy. Females of reproductive potential must also have a negative pregnancy test when applicable.

    Sohonos is considered not medically necessary when the member does not meet the continuation criteria, including applicable age requirements, evidence of therapeutic benefit, safety requirements, reproductive-status requirements, and the restriction against combination use with Pasatru (garetosmab-grts).

    Provider Actions

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Sohonos (palovarotene). Authorization may be granted for 12 months for initial or continued treatment when the applicable criteria are met.

    • Initial authorization: criteria for reduction in the volume of new heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) must be satisfied.
    • Continuation authorization: criteria for reauthorization must be satisfied, including documented benefit from therapy.
    Documentation Required

    Initial-Request Documentation

    Submit the following documentation with an initial request to support the diagnosis and applicable clinical findings.

    • Genetic testing confirming FOP with a documented pathogenic activin receptor type 1 (ACVR1) FOP-causing mutation, such as R206H.
    • Chart notes or medical records supporting signs and symptoms of FOP, including congenital malformation of the great toe and episodic soft-tissue swelling and/or ectopic ossification in ligament or muscle tissue.

    Background

    Sohonos (palovarotene) is indicated for adults and pediatric patients with fibrodysplasia ossificans progressiva (FOP) to reduce the volume of new heterotopic ossification. FOP is associated with a pathogenic activin receptor type 1 (ACVR1) variant and clinical findings such as congenital great-toe malformation, episodic soft-tissue swelling, and ectopic ossification in ligament or muscle tissue.

    Definitions

    Fibrodysplasia ossificans progressiva (FOP)
    Policy definitionA rare disorder caused by a pathogenic ACVR1 FOP-causing variant.
    Characteristic findingCongenital malformation of the great toe.
    Additional signs and symptomsEpisodic soft-tissue swelling and/or ectopic ossification in ligament or muscle tissue.
    Heterotopic ossification (HO)
    DefinitionAbnormal bone formation in soft tissues.
    Treatment contextSohonos is used to reduce the volume of new heterotopic ossification.
    Associated condition

    Initial Therapy Criteria

    Initial Authorization

    Authorization of 12 months may be granted for reduction in the volume of new heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) when all of the following criteria are met.

    Initial authorization

    • Diagnosis and clinical findings: Member has a genetic test indicating a pathogenic ACVR1 FOP-causing variant, such as R206H, and signs and symptoms of FOP, including congenital malformation of the great toe and episodic soft-tissue swelling and/or ectopic ossification in ligament or muscle tissue.
    • Medical stability: Member has no significant uncontrolled comorbid illness, such as cardiac, neurologic, or rheumatologic illness.
    • Age requirement

      • Male age criterion:

    Continuation Criteria

    Continuation Authorization

    Authorization of 12 months may be granted for continued treatment when the continuation criteria are met.

    Continuation authorization

    • Age requirement

      • Male age criterion: Member is a male 10 years of age or older.>=10 years
      • Female age criterion: Member is a female 8 years of age or older.>=8 years
    • Therapeutic benefit:

    Quantity Limits and Dosing

    Sohonos (palovarotene) capsule 1 mg
    MedicationSohonos (palovarotene) capsule 1 mg.
    Quantity limit28 capsules.
    Limit periodPer 28 days.
    Sohonos (palovarotene) capsule 1.5 mg
    MedicationSohonos (palovarotene) capsule 1.5 mg.
    Quantity limit56 capsules.
    Limit periodFor 28 days.
    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicySohonos (palovarotene) coverage for fibrodysplasia ossificans progressiva
    Policy CodePolicy 05.05.17
    Change TypeNo material clinical or coverage change
    Effective DateDec 9, 202621d
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization to initiate or continue Sohonos treatment.
    SourceLink
    On This Page
    Coverage CriteriaProvider ActionsBackgroundDefinitionsInitial Therapy CriteriaContinuation CriteriaQuantity Limits and Dosing
    Disease stability or improvement
  1. Safety: Member has had no serious adverse event that would contraindicate continued therapy, such as premature epiphyseal closure in growing pediatric patients or mucocutaneous adverse reactions.No contraindicating serious adverse event
  2. Reproductive safety: Females of reproductive potential have a negative pregnancy test; the member is not currently breastfeeding, pregnant, or planning pregnancy.Negative pregnancy test when applicable
  3. Combination restriction: Sohonos will not be used in combination with Pasatru (garetosmab-grts).
  4. Documentation Required

    Continuation Documentation

    Submit chart notes or medical record documentation with a continuation request to demonstrate that the member is benefiting from therapy.

    • Document disease stability or improvement, such as stability or reduction in the volume of new heterotopic ossification.
    • Document that the member continues to meet the applicable continuation criteria, including age, reproductive-status, and concomitant-therapy requirements.
    Note

    Qualified Prescriber

    Sohonos must be prescribed by, or prescribed in consultation with, a physician experienced in treating FOP.

    • Examples include an endocrinologist, orthopedist, rheumatologist, or neurologist with experience treating FOP.
    Denial Risk

    Initial Approval Criteria Not Met

    The initial request is at risk for denial when the member does not satisfy all applicable initial approval criteria.

    • No genetic confirmation of a pathogenic ACVR1 FOP-causing variant, such as R206H.
    • FOP diagnosis is not supported by the required signs and symptoms or medical records.
    • Other initial criteria are not met, including applicable age, pregnancy or breastfeeding restrictions, uncontrolled comorbid illness, or the requirement not to use Sohonos with Pasatru (garetosmab-grts).
    Denial Risk

    Continuation Criteria Not Met

    A continuation request is at risk for denial when the member does not satisfy all applicable continuation criteria.

    • The member is not experiencing benefit from therapy, as evidenced by lack of disease stability or improvement.
    • A serious adverse event contraindicates continued therapy, such as premature epiphyseal closure in a growing pediatric patient or mucocutaneous adverse reactions.
    • Other continuation criteria are not met, including applicable age, pregnancy or breastfeeding restrictions, or the requirement not to use Sohonos with Pasatru (garetosmab-grts).
    Denial Risk

    Not Medically Necessary

    Sohonos (palovarotene) is considered not medically necessary when the member does not meet the applicable continuation-of-therapy criteria.

    • This includes failure to demonstrate benefit from therapy or the presence of a serious adverse event that contraindicates continued treatment.
    The policy addresses heterotopic ossification in members with fibrodysplasia ossificans progressiva (FOP).
    Member is a male 10 years of age or older.
    >=10 years
  5. Female age criterion: Member is a female 8 years of age or older.>=8 years
  6. Reproductive safety: Females of reproductive potential should have a negative pregnancy test, and the member is not currently breastfeeding, pregnant, or planning pregnancy.Negative pregnancy test when applicable
  7. Combination restriction: The requested medication will not be used in combination with Pasatru (garetosmab-grts).
  8. Member is experiencing benefit from therapy as evidenced by disease stability or disease improvement, such as stability or reduction in the volume of new heterotopic ossification.
    Disease stability or improvement
  9. Safety: Member has had no serious adverse event that would contraindicate continued therapy, such as premature epiphyseal closure in growing pediatric patients or mucocutaneous adverse reactions.No contraindicating serious adverse event
  10. Reproductive safety: Females of reproductive potential should have a negative pregnancy test, and the member is not currently breastfeeding, pregnant, or planning pregnancy.Negative pregnancy test when applicable
  11. Combination restriction: The requested medication will not be used in combination with Pasatru (garetosmab-grts).
  12. Sohonos (palovarotene) capsule 2.5 mg
    MedicationSohonos (palovarotene) capsule 2.5 mg.
    Quantity limit28 capsules.
    Limit periodPer 28 days.
    Sohonos (palovarotene) capsule 5 mg
    MedicationSohonos (palovarotene) capsule 5 mg.
    Quantity limit28 capsules.
    Limit periodPer 28 days.
    Sohonos (palovarotene) capsule 10 mg
    MedicationSohonos (palovarotene) capsule 10 mg.
    Quantity limit56 capsules.
    Limit periodPer 28 days.
    Sohonos (palovarotene) 1 mg capsule
    Applicable patientsAdults and pediatric patients 14 years and older.
    Usual dose5 mg once daily.
    Flare-up dose20 mg once daily for 4 weeks, followed by 10 mg once daily for 8 weeks.
    Sohonos (palovarotene) 2.5 mg capsule
    Applicable patientsPediatric patients 13 years and younger.
    Dose range2.5 mg to 5 mg once daily.
    Dose determinationDose is based on weight.
    Sohonos (palovarotene) 5 mg capsule
    Flare-up dose10 mg to 20 mg once daily for 4 weeks.
    Maintenance dose5 mg to 10 mg daily for 8 weeks.
    Treatment sequenceThe maintenance dose follows the 4-week flare-up dose.